Phase 2 Clinical Trial of NanoPac® for Treatment of Mucinous Cysts of the Pancreas

[Northerner]

[URL='http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fnanology.us%2F&esheet=51710980&newsitemid=20171107005060&lan=en-US&anchor=NanOlogy+LLC&index=1&md5=6dea4a97e1a22ec686076becfb989f65']NanOlogy LLC[/URL], a clinical-stage pharmaceutical development company, today announced the first patient has been enrolled in a clinical trial of NanoPac® (nanoparticle paclitaxel) sterile suspension for treatment of mucinous cystic neoplasms (MCNs) of the pancreas. The Phase 2 dose-rising trial will evaluate the safety and preliminary efficacy of NanoPac delivered directly into MCNs by endoscopic ultrasound-guided fine needle injection.

NanoPac is part of an extensive submicron technology platform developed by NanOlogy. Gere diZerega, MD, VP of Medical Affairs, will present an overview of the platform and an update of the clinical program during the Biotech Showcase™, January 8-10, 2018, in San Francisco.

“There is no approved drug treatment for patients with MCNs who are at high risk for progression to cancer,” said Dr. diZerega. “This clinical trial is the first study in humans to examine whether NanoPac injected intracystically will safely chemically ablate the cyst with a high locally sustained concentration of the drug.”

http://www.businesswire.com/news/ho...™-Announces-Patient-Enrolled-Phase-2-Clinical

 

[eggyg]

NanOlogy LLC, a clinical-stage pharmaceutical development company, today announced the first patient has been enrolled in a clinical trial of NanoPac® (nanoparticle paclitaxel) sterile suspension for treatment of mucinous cystic neoplasms (MCNs) of the pancreas. The Phase 2 dose-rising trial will evaluate the safety and preliminary efficacy of NanoPac delivered directly into MCNs by endoscopic ultrasound-guided fine needle injection.

NanoPac is part of an extensive submicron technology platform developed by NanOlogy. Gere diZerega, MD, VP of Medical Affairs, will present an overview of the platform and an update of the clinical program during the Biotech Showcase™, January 8-10, 2018, in San Francisco.

“There is no approved drug treatment for patients with MCNs who are at high risk for progression to cancer,” said Dr. diZerega. “This clinical trial is the first study in humans to examine whether NanoPac injected intracystically will safely chemically ablate the cyst with a high locally sustained concentration of the drug.”

http://www.businesswire.com/news/home/20171107005060/en/NanOlogy™-Announces-Patient-Enrolled-Phase-2-Clinical

That’s exactly what I had and the only available treatment was for me resection of the pancreas. This would be great if it does become widely available. I wonder though if it would damage the pancreas in any way therefore diabetes could still rear it’s ugly head! Touch wood the trial has a good outcome.

 

[Northerner]

That’s exactly what I had and the only available treatment was for me resection of the pancreas. This would be great if it does become widely available. I wonder though if it would damage the pancreas in any way therefore diabetes could still rear it’s ugly head! Touch wood the trial has a good outcome.

I knew someone would be interested in this! 🙂